In the Literature

Nurse-led survivorship care programs may improve the health and resiliency of caregivers of patients with advanced head and neck cancer, according to data from a recently published randomized controlled trial. Read More ›

Peer-to-peer (PTP) support is an important aspect of nonprofessional patient care that improves cancer-specific quality of life. However, PTP research is sorely lacking, with very few randomized controlled trials being conducted in this space, as well as a lack of standardized quality parameters for what constitutes successful and efficient PTP support, according to newly published research. Read More ›

A new study has found that partners of colorectal cancer survivors experienced long-term financial toxicity that was associated with worse health-related quality of life due to systems- and individual-level behavioral factors. Read More ›

Standard pediatric chemotherapy regimens used in the treatment of children and adolescents with high-risk Hodgkin lymphoma are often associated with late effects, including second cancers, infertility, and cardiovascular disease, as well as significantly reduced overall survival (OS). Read More ›

Induction chemotherapy leads to remission in many patients with acute myeloid leukemia (AML) aged ≥60 years; however, the disease relapses in most patients, resulting in poor overall survival (OS). Read More ›

  • Selpercatinib Shows Durable Responses in Patients with Thyroid Cancer and RET Mutation
  • Venclexta plus Azacitidine Improves Overall Survival in Patients with AML
  • Advances in New Therapies Attributed to Reductions in Lung Cancer Mortality
Read More ›

  • Selinexor-Dexamethasone Combination Improves Outcomes in Patients with Multiple Myeloma Refractory to 3 Drug Classes
  • Five-Year Survival Rates with BRAF-MEK Inhibitors in Metastatic Melanoma with BRAF Mutation
Read More ›

  • New Triple-Drug Regimen for Newly Diagnosed Patients with Multiple Myeloma
  • Alpelisib Prolongs Progression-Free Survival in Advanced Breast Cancer with PIK3CA Mutation
  • Long-Term Outcomes Affect Cost-Effectiveness of CAR T-Cell Therapy for DLBCL
Read More ›

Currently, there are limited therapies to prevent or delay recurrence in advanced ovarian cancer, with approximately 70% of patients having a recurrence within 3 years. The effectiveness of olaparib, an oral poly (ADP-ribose) polymerase inhibitor, in relapsed disease has been well-established; however, its benefit as a maintenance therapy in newly diagnosed advanced ovarian cancer is uncertain. Read More ›

Page 1 of 2

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: